Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naoxueshu oral liquid registry study for prevention and treatment of cerebral hemorrhage
ChiCTR2300074892Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Jan 2022
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of naoxueshu in brain hemorrhage (ICH), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoints: Reduced hematoma volume and proportion at day 14 or discharge, New stroke events within 12 months and 2 more. Started Jan 2022; status: recruiting.
02
Drugs
naoxueshu
03
Conditions
brain hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR2300074892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074892.